Literature DB >> 20168275

Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India.

Taliva D Martin1, Sivakumar R Rathinam, Emmett T Cunningham.   

Abstract

PURPOSE: The purpose of this study was to describe the prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease seen at a uveitis referral center in South India.
METHODS: Charts of patients with Vogt-Koyanagi-Harada disease examined in the uveitis referral clinic of Aravind Eye Hospital between January 1998 and December 2007 were reviewed. A subset of patients <or=16 years of age was identified, and the clinical characteristics and causes of vision loss were evaluated.
RESULTS: Vogt-Koyanagi-Harada disease was diagnosed in 267 of 22,959 patients (1.2%) during the study period. Twenty-two children (8.2%) were identified, including 13 girls (59.1%) and 9 boys (40.9%). Age at presentation ranged from 8 years to 16 years, with a mean and a median of 12.6 and 13.5 years, respectively. The most common complaints were blurred vision (39 eyes, 88.6%) and eye redness (36 eyes, 81.8%). Fifteen (68.5%) children had headaches, 6 (27.3%) developed meningismus and alopecia, 4 (18.2%) developed poliosis and vitiligo, and 3 (13.6%) had tinnitus or dysacusis. Initially, all were treated with oral prednisone, but 12 (54.6%) required methotrexate, 5 (22.7%) required azathioprine, and 2 (9.1%) required cyclophosphamide. Seventy-five percent of eyes had a final visual acuity of >or=20/40, whereas 13.6% had a final visual acuity of <or=20/200.
CONCLUSION: Vogt-Koyanagi-Harada disease is an uncommon cause of uveitis in children. The clinical characteristics of pediatric Vogt-Koyanagi-Harada disease in South India resembled those described in cohorts from other regions. Although children in our cohort tended to do well with prompt diagnosis and treatment, long-term vision loss can occur.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20168275     DOI: 10.1097/IAE.0b013e3181c96a87

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Spectrum and visual outcomes of Vogt-Koyanagi-Harada disease in Argentina.

Authors:  Verónica E Giordano; Ariel Schlaen; Martín J Guzmán-Sánchez; Cristobal Couto
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

2.  Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.

Authors:  Massimo Accorinti; Maria Carmela Saturno; Ludovico Iannetti; Priscilla Manni; Davide Mastromarino; Maria Pia Pirraglia
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 3.  Vogt-Koyanagi-Harada syndrome - current perspectives.

Authors:  Abeir Baltmr; Sue Lightman; Oren Tomkins-Netzer
Journal:  Clin Ophthalmol       Date:  2016-11-24

4.  Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.

Authors:  Sikander Ak Lodhi; Jm Lokabhi Reddy; Venkataratnam Peram
Journal:  Clin Ophthalmol       Date:  2017-08-07

5.  Identification of immune hub genes participating in the pathogenesis and progression of Vogt-Koyanagi-Harada disease.

Authors:  Yiqi Wang; Yahan Ju; Jiajing Wang; Na Sun; Zhimin Tang; Huiqin Gao; Ping Gu; Jing Ji
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 6.  Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.

Authors:  Marcelo Mendes Lavezzo; Viviane Mayumi Sakata; Celso Morita; Ever Ernesto Caso Rodriguez; Smairah Frutuoso Abdallah; Felipe T G da Silva; Carlos Eduardo Hirata; Joyce Hisae Yamamoto
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

7.  Unusual case of vitiligo reversal in Vogt-Koyanagi-Harada syndrome.

Authors:  Praveen Subudhi; Zahiruddin Khan; B Nageswar Rao Subudhi; Silla Sitaram
Journal:  Indian J Ophthalmol       Date:  2017-09       Impact factor: 1.848

Review 8.  Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment.

Authors:  Laura Girasoli; Diego Cazzador; Roberto Padoan; Ennio Nardello; Mara Felicetti; Elisabetta Zanoletti; Franco Schiavon; Roberto Bovo
Journal:  J Immunol Res       Date:  2018-09-26       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.